Present and Future Dyslipidemia Therapies for Reducing Cardiovascular Risk and Cardiovascular Disease Incidence
Academic Press Inc (Verlag)
978-0-323-90056-0 (ISBN)
Dyslipidemia Therapies for Reducing Cardiovascular Disease Risk provides an overview of the latest research and developments in dyslipidemia therapies to combat elevated lipid levels leading to atherosclerotic cardiovascular disease (ASCVD). A translational medicine approach is used to discuss the background on key lipid disorders in the population leading to cardiovascular disease; clinical trial development of the new drug therapies to combat the lipid disorders and their mechanisms of action; and the target patient groups of the therapies and how they address unmet medical needs in cardiovascular disease/lipid disorders. Contributions from leaders in the dyslipidemia, metabolic and cardiology fields, they offer insights into the research and development and medical backgrounds of the new drug therapies, as well as unpublished information regarding the challenges in unmet medical needs with respect to dyslipidemia in the population, clinical trial development of the therapies and future goals for the therapies.
Shirya Rashid has a Ph.D. in Medical Sciences from the University of Toronto. She was a tenured Associate Professor in the Departments of Pharmacology & Medicine at Dalhousie & McMaster Universities in Canada. Her translational research interest is in cardiovascular diseases, focusing on lipid metabolism at the molecular, cellular, mouse in vivo & clinical levels. She was the first to create the PCSK9 gene-deleted mouse model, uncovering the physiological function of PCSK9 in degrading the LDL receptor & leading to the PCSK9 inhibitory drug therapies (eg alirocumab), highly effective in reducing cardiovascular disease. She has 38+ publications (most in high-impact journals), 2 book chapters, 40+ abstracts, 31+ invited & 28+ conference speaker presentations & 8 patents/copyrights.
1. The case for updated lower lipid targets for greater cardiovascular risk reduction
2. The role of established therapies for LDL-cholesterol lowering – statins and ezetimibe
3. PCSK9 monoclonal antibodies and LDL-cholesterol lowering
4. PCSK9 siRNAs as novel therapy for elevated LDL-cholesterol in patients at cardiovascular disease risk
5. Bempadoic Acid as a novel pathway targeting LDL-cholesterol
6. The Role of CETP inhibitors in LDL-cholesterol lowering
7. Beyond LDL-cholesterol, Lp(a) as a therapeutic target
8. Beyond LDL-cholesterol, triglycerides as a therapeutic target effectively reduced by icosapent ethyl
9. Beyond LDL-cholesterol, novel targets: apoCIII, MTP, endothelial lipase and AngPTL3 inhibitors
| Erscheint lt. Verlag | 1.6.2024 |
|---|---|
| Verlagsort | Oxford |
| Sprache | englisch |
| Maße | 151 x 229 mm |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Kardiologie / Angiologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Naturwissenschaften ► Biologie | |
| ISBN-10 | 0-323-90056-9 / 0323900569 |
| ISBN-13 | 978-0-323-90056-0 / 9780323900560 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
